Prodrugs: A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Drug Discovery: The process of finding chemicals for potential therapeutic use.Biota: The spectrum of different living organisms inhabiting a particular region, habitat, or biotope.Drug Evaluation, Preclinical: Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.Molecular Structure: The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.Chemistry, Pharmaceutical: Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.Pharmaceutical Preparations: Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.Tablets: Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed)Inventions: A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.Embolization, Therapeutic: A method of hemostasis utilizing various agents such as Gelfoam, silastic, metal, glass, or plastic pellets, autologous clot, fat, and muscle as emboli. It has been used in the treatment of spinal cord and INTRACRANIAL ARTERIOVENOUS MALFORMATIONS, renal arteriovenous fistulas, gastrointestinal bleeding, epistaxis, hypersplenism, certain highly vascular tumors, traumatic rupture of blood vessels, and control of operative hemorrhage.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Disseminated Intravascular Coagulation: A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.Substance P: An eleven-amino acid neurotransmitter that appears in both the central and peripheral nervous systems. It is involved in transmission of PAIN, causes rapid contractions of the gastrointestinal smooth muscle, and modulates inflammatory and immune responses.Ultrasonography, Interventional: The use of ultrasound to guide minimally invasive surgical procedures such as needle ASPIRATION BIOPSY; DRAINAGE; etc. Its widest application is intravascular ultrasound imaging but it is useful also in urology and intra-abdominal conditions.Intellectual Property: Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)Foramen Ovale, Patent: A condition in which the FORAMEN OVALE in the ATRIAL SEPTUM fails to close shortly after birth. This results in abnormal communications between the two upper chambers of the heart. An isolated patent ovale foramen without other structural heart defects is usually of no hemodynamic significance.Substance-Related Disorders: Disorders related to substance abuse.Antithrombin III: A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.Antithrombin III Deficiency: An absence or reduced level of Antithrombin III leading to an increased risk for thrombosis.Antithrombins: Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.Antithrombin Proteins: An endogenous family of proteins belonging to the serpin superfamily that neutralizes the action of thrombin. Six naturally occurring antithrombins have been identified and are designated by Roman numerals I to VI. Of these, Antithrombin I (see FIBRIN) and ANTITHROMBIN III appear to be of major importance.Factor Xa: Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.Gait: Manner or style of walking.Heparin: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.Thrombin: An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.Gait Disorders, Neurologic: Gait abnormalities that are a manifestation of nervous system dysfunction. These conditions may be caused by a wide variety of disorders which affect motor control, sensory feedback, and muscle strength including: CENTRAL NERVOUS SYSTEM DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; NEUROMUSCULAR DISEASES; or MUSCULAR DISEASES.Heparin Cofactor II: A sulfated plasma protein with a MW of approximately 66kDa that resembles ANTITHROMBIN III. The protein is an inhibitor of thrombin in plasma and is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily.Immunoglobulin Variable Region: That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.Illusions: The misinterpretation of a real external, sensory experience.Immunoglobulin Light Chains: Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.Immunoglobulin Heavy Chains: The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.Immunoglobulin Fragments: Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Complementarity Determining Regions: Three regions (CDR1; CDR2 and CDR3) of amino acid sequence in the IMMUNOGLOBULIN VARIABLE REGION that are highly divergent. Together the CDRs from the light and heavy immunoglobulin chains form a surface that is complementary to the antigen. These regions are also present in other members of the immunoglobulin superfamily, for example, T-cell receptors (RECEPTORS, ANTIGEN, T-CELL).Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Eritrea: A country of eastern Africa, west of the Red Sea, bordered west and northwest by SUDAN, and south by ETHIOPIA. Its capital is Asmara.Molluginaceae: A plant family of the order Caryophyllales, subclass Caryophyllidae, class Magnoliopsida. Some members contain triterpenoid saponins.Drug Industry: That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.Biotechnology: Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.Outsourced Services: Organizational activities previously performed internally that are provided by external agents.Crops, Agricultural: Cultivated plants or agricultural produce such as grain, vegetables, or fruit. (From American Heritage Dictionary, 1982)Education, Distance: Education via communication media (correspondence, radio, television, computer networks) with little or no in-person face-to-face contact between students and teachers. (ERIC Thesaurus, 1997)Reagent Kits, Diagnostic: Commercially prepared reagent sets, with accessory devices, containing all of the major components and literature necessary to perform one or more designated diagnostic tests or procedures. They may be for laboratory or personal use.Computer-Assisted Instruction: A self-learning technique, usually online, involving interaction of the student with programmed instructional materials.Aptitude: The ability to acquire general or special types of knowledge or skill.Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.Antipsychotic Agents: Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.Biological Control Agents: Organisms, biological agents, or biologically-derived agents used strategically for their positive or adverse effect on the physiology and/or reproductive health of other organisms.Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)Halogenated Diphenyl Ethers: Compounds that contain two halogenated benzene rings linked via an OXYGEN atom. Many polybrominated diphenyl ethers are used as FLAME RETARDANTS.Organosilicon Compounds: Organic compounds that contain silicon as an integral part of the molecule.Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.DibenzothiazepinesBenzodiazepines: A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring.Vinblastine: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)Catharanthus: A plant genus of the family Apocynaceae. It is the source of VINCA ALKALOIDS, used in leukemia chemotherapy.Vinca Alkaloids: A group of indole-indoline dimers which are ALKALOIDS obtained from the VINCA genus of plants. They inhibit polymerization of TUBULIN into MICROTUBULES thus blocking spindle formation and arresting cells in METAPHASE. They are some of the most useful ANTINEOPLASTIC AGENTS.Secologanin Tryptamine Alkaloids: Compounds formed by condensation of secologanin with tryptamine resulting in a tetrahydro-beta-carboline which is processed further to a number of bioactive compounds. These are especially found in plants of the APOCYNACEAE; LOGANIACEAE; and RUBIACEAE families.Indole Alkaloids: Group of alkaloids containing a benzylpyrrole group (derived from TRYPTOPHAN)Dehydration: The condition that results from excessive loss of water from a living organism.Aromatic-L-Amino-Acid Decarboxylases: An enzyme group with broad specificity. The enzymes decarboxylate a range of aromatic amino acids including dihydroxyphenylalanine (DOPA DECARBOXYLASE); TRYPTOPHAN; and HYDROXYTRYPTOPHAN.Antineoplastic Agents, Phytogenic: Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.Stereoisomerism: The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)United States National Aeronautics and Space Administration: An independent Federal agency established in 1958. It conducts research for the solution of problems of flight within and outside the Earth's atmosphere and develops, constructs, tests, and operates aeronautical and space vehicles. (From U.S. Government Manual, 1993)National Library of Medicine (U.S.): An agency of the NATIONAL INSTITUTES OF HEALTH concerned with overall planning, promoting, and administering programs pertaining to advancement of medical and related sciences. Major activities of this institute include the collection, dissemination, and exchange of information important to the progress of medicine and health, research in medical informatics and support for medical library development.Surgical Mesh: Any woven or knit material of open texture used in surgery for the repair, reconstruction, or substitution of tissue. The mesh is usually a synthetic fabric made of various polymers. It is occasionally made of metal.United StatesNational Health Insurance, United StatesPolypropylenes: Propylene or propene polymers. Thermoplastics that can be extruded into fibers, films or solid forms. They are used as a copolymer in plastics, especially polyethylene. The fibers are used for fabrics, filters and surgical sutures.MEDLARS: A computerized biomedical bibliographic storage and retrieval system operated by the NATIONAL LIBRARY OF MEDICINE. MEDLARS stands for Medical Literature Analysis and Retrieval System, which was first introduced in 1964 and evolved into an online system in 1971 called MEDLINE (MEDLARS Online). As other online databases were developed, MEDLARS became the name of the entire NLM information system while MEDLINE became the name of the premier database. MEDLARS was used to produce the former printed Cumulated Index Medicus, and the printed monthly Index Medicus, until that publication ceased in December 2004.Waiting Lists: Prospective patient listings for appointments or treatments.Th2 Cells: Subset of helper-inducer T-lymphocytes which synthesize and secrete the interleukins IL-4, IL-5, IL-6, and IL-10. These cytokines influence B-cell development and antibody production as well as augmenting humoral responses.Libraries, MedicalDirectories as Topic: Lists of persons or organizations, systematically arranged, usually in alphabetic or classed order, giving address, affiliations, etc., for individuals, and giving address, officers, functions, and similar data for organizations. (ALA Glossary of Library and Information Science, 1983)K562 Cells: An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS.DirectoryH(+)-K(+)-Exchanging ATPaseSoftware: Sequential operating programs and data which instruct the functioning of a digital computer.Vitamin K: A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.Internet: A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.Parents: Persons functioning as natural, adoptive, or substitute parents. The heading includes the concept of parenthood as well as preparation for becoming a parent.

Effects of 2,2'-O-cyclocytidine and acyclovir on latent herpes simplex virus in trigeminal ganglia of mice. (1/4)

The effects of 2,2'-O-cyclocytidine (CC) and acyclovir (ACV) on latent herpes simplex virus (HSV) in trigeminal ganglia were studied in an in vitro model using reactivation of HSV type 1 (HSV-1) as a model. It was shown that both CC (10 micrograms/ml) and ACV (2.5 micrograms/ml) significantly inhibited the reactivation of the latent HSV-1 in infected ganglia. The effect of CC (25 micrograms/ml), which was as good as that of ACV (10 micrograms/ml), did not last as long as that of ACV after removal of the drugs. The latent state of HSV-1 in vitro was dependent on the continuous presence of either drug. Even though the latent HSV-1 could not be eliminated completely from the trigeminal ganglia by discontinuous administration of either drug, its titers were markedly reduced. The combination of CC and ACV had a synergistic effect on preventing the reactivation of the latent HSV-1 in vitro.  (+info)

Antiviral activities of acyl derivatives of 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosylcytosine in cell culture. (2/4)

Antiviral activities of acyl derivatives (3'-O-octanoyl and 3'-O-decanoyl) of 2,2'-anhydro-1-beta-d-arabinofuranosylcytosine (cyclo-C) and 1-beta-d-arabinofuranosylcytosine (Ara-C) were compared with other antiviral nucleosides, and some biological characteristics of the antiviral activity were investigated. Among those synthesized acyl derivatives, 3'-O-decanoyl ara-C was the most active against deoxyribonucleic acid viruses, with an activity comparable to that of Ara-C. Acyl derivatives of cyclo-C were somewhat less active than their Ara-C counterparts. In the value of therapeutic index, 1-beta-d-arabinofuranosyladenine was superior to the others, followed by 5-iodo-2'-deoxyuridine. In comparing the sensitivity of two serotypes of herpes simplex virus it was found that Ara-C and its ester, as well as its cyclo-C counterpart, were more active against the type 2 than the type 1 strain. The activity of 3'-O-decanoyl Ara-C, like that of its parent, was diminished by treatment with cytidine deaminase from mouse kidney, but 3'-O-decanoyl cyclo-C was resistant to this treatment. In comparative studies of 3'- and 5'-O-acyl Ara-C's, antivaccinia virus activity of 3'-O-palmitoyl Ara-C was significantly superior to its 5'-counterpart. The inhibitory activity of 5'-O-decanoyl Ara-C was markedly reduced by the presence of a threefold molar excess of eserine sulfate, a choline esterase inhibitor, whereas the 3'-acyl Ara-C was not affected by the inhibitor in any combination. This result indicates that enzymatic hydrolysis of the 3'-ester to Ara-C, which is inhibited by eserine sulfate, did not occur in this cell culture.  (+info)

Synergistic effects of the combination of cis-platinum diamminodichloride and 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in transplanted mouse leukemias. (3/4)

cis-Platinum diamminodichloride has been studied in combination with 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine on an every-4-day schedule in various lines of mouse leukemia. This combination is synergistic in leukemias L1210 and P388 and sublines made resistant to 5-fluorouracil or methotrexate. There is no cross-resistance between cis-platinum diamminodichloride and 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine, but the combination is no more effective against lines of leukemia made resistant to cis-platinum diamminodichloride or to 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine than either single active compound alone. Since these compounds have no cross-resistance, act by quite different mechanisms of action, and have different limiting toxicity, the combination is now being evaluated clinically.  (+info)

Tyramine-like effect of cyclocytidine (2,2'-anhydro-1-beta-arabinofuranosylcytosine hydrochloride), an antineoplastic agent. (4/4)

Since cyclocytidine (2,2'-anhydro-1-beta-arabinofuranosylcytosine hydrochloride) was introduced as an antineoplastic agent for the treatment of lymphatic leukemia, sinus acceleration and an increase in systemic blood pressure has been reported as its systemic effects in the clinical cases. These cardiovascular effects of cyclocytidine were observed also in anesthetized dogs, but not in reserpine-pretreated animals. Increases in heart rate and in systemic blood pressure were prevented by propranolol and phentolamine, respectively. The mechanism of these sympathomimetic effects was further analysed in the excised, blood-perfused canine sinoatrial node and papillary muscle preparations with a support dog. Positive chronotropic and inotropic responses to cyclocytidine were abolished by desipramine, propanolol, and pretreatment with reserpine but not by tetrodotoxin and hexamethonium. The tyramine-like actions of cyclocytidine at adrenergic neuronal terminals were discussed in conjunction with the uptake mechanism of the drug into the tumor cells.  (+info)

*List of drugs: An-Ap

... ancitabine (INN) Ancobon Ancotyl ancriviroc (USAN) ancrod (INN) andolast (INN) Andriol Androcur Androderm Androgel Android-f ...

*List of MeSH codes (D13)

... ancitabine MeSH D13.570.685.245.500 --- deoxycytidine MeSH D13.570.685.245.500.250 --- bromodeoxycytidine MeSH D13.570.685.245. ... ancitabine MeSH D13.570.065.950 --- vidarabine MeSH D13.570.230.229 --- deoxyadenosines MeSH D13.570.230.229.075 --- cladribine ...
BH-AC-AMP protocol: chemotherapy protocol consisting of N(4)-behenoyl-1-beta-arabinofuranosylcytosine, aclarubicin, 6-mercaptopurine & prednisolone
Classifying the isomeric 4-amino-cyclohexane-carboxylic acids and their acyl derivatives in the cis- or trans series is certain thanks to the investigations of J Houben and A Pfau, Ber dtsch chem Ges 49 2294 (1916), L Orthner and R Hein (Biochem Z 262 461 (1933), G Wendt (Chem Ber 75 425 (1942) and E Ferber and H Br ckner (Chem Ber 76 1019 (1943).. As the acid saponification in mild conditions of the ethyl ester prepared from the amino acids and their hydrochlorides returned to the respective starting product only, the steric classification can be considered valid for the ethyl esters too.. Spectroscopic investigation of the constitution of the amides prepared confirmed their constitution. Comparison of the IR photos of cis-cis-IV, trans-trans-IV and cis-trans-IV as well as cis-VI and trans-VI shows that the compounds in the cis- and trans-series have the same configuration.. The differing steric alignment of the COOC2H5 group in the cis- and trans-forms is evident from the homogenous shifts in ...
CISPLATIN Kemasan : vial 10 mg/20 cc, 25 mg/50 cc Cara melarutkan: Setiap 1 mg cis-platinum dilarutkan dengan 1 cc aquabidest. Dosis : 100 mg/m2 Premedikasi : inj Ondansentron 0,1 - 0,2 mg/kgBB/ 6-12 jam Cara pemberian : Jalur 1 : lakukan hidrasi dengan larutan 2A 250cc selama 6 - 8 jam -|…
Gibson, M H. and Bertalanffy, F D., "In vivo synchrony of solid b16 melanoma by 1-beta-d-arabinofuranosyl- -cytosine (ara-c). Abstr." (1971). Subject Strain Bibliography 1971. 68 ...
La butirril-CoA deidrogenasi è un enzima appartenente alla classe delle ossidoreduttasi, che catalizza la seguente reazione: butirril-CoA + accettore ⇄ 2-butenoil-CoA + accettore ridotto Lenzima è una flavoproteina; forma, con unaltra flavoproteina e lenzima flavoproteina deidrogenasi (trasferisce elettroni) (numero EC 1.5.5.1), un sistema che riduce lubichinone ed altri accettori. ^ (EN) 1.5.5.1, in ExplorEnz - The Enzyme Database, IUBMB. Mahler, H.R., Studies on the fatty acid oxidizing system of animal tissue. IV. The prosthetic group of butyryl coenzyme A dehydrogenase, in J. Biol. Chem., vol. 206, 1954, pp. 13-26, Entrez PubMed 13130522. Hauge, J.G., Crane, F.L. and Beinert, H., On the mechanism of dehydrogenation of fatty acyl derivatives of coenzyme A. III. Palmityl CoA dehydrogenase, in J. Biol. Chem., vol. 219, 1956, pp. 727-733, Entrez PubMed 13319294. Green, D.E., Mii, S., Mahler, H.R. and Bock, R.M., Studies on the fatty acid oxidizing system of animal tissue. III. Butyryl ...
So there I was, puffing and dreaming about the finish point when, out of the corner of my eye, a green-helmeted about nine year old boy appeared riding a slender, jet-black bmx. At first, I thought he would whiz uneventfully by or, at most, stick out his hand for a passing high-five which is the customary practice of some of the other kids of the area. This kid was far more ambitious ...
B-Specific) Enoyl-(Acyl-Carrier Protein) Reductase (NADPH: An enzyme that catalyzes the oxidation of acyl-[acyl-carrier protein] to trans-2,3-dehydroacyl-[acyl-carrier protein] in the fatty acid biosynthesis pathway. It has a preference for acyl derivatives with carbon chain length from 4 to 16.
2 For my friends. Aware of how they worry about me and of how terrible I am when it comes to staying in touch, I want them to know that I still feel them lifting me up ...
The use of a prodrug, a conjugate of an active drug with a lipophilic substituent, is a good way of increasing the cutaneous absorption of a drug. However, the activity of dermal hydrolases has rarely been investigated in humans, or experimental animals. In the present study, we focused on the identification of rat dermal esterases and the hydrolysis of a prodrug during permeation across rat skin. We found that carboxylesterase (CES), especially the rat CES1 isozyme, Hydrolase A, is expressed in rat skin and that the hydrolysis of p-nitrophenyl acyl derivatives and caproyl-propranolol (PL) was 20-fold lower in the 9000g supernatant fraction of skin homogenate than in liver microsomes. A permeation study of caproyl-PL was performed in rat full-thickness and stripped skin using a flow-through diffusion cell. Caproyl-PL was easily partitioned into the stratum corneum and retained, not only in the stratum corneum, but also in viable epidermis and dermis. Caproyl-PL could barely be detected in the receptor

Systems and methods for treating cancer and/or augmenting organ function - Autonomix Medical, Inc.Systems and methods for treating cancer and/or augmenting organ function - Autonomix Medical, Inc.

... pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, ...
more infohttp://www.freepatentsonline.com/10136944.html

WO2003000236A1 - Particles with improved solubilization capacity 
        - Google PatentsWO2003000236A1 - Particles with improved solubilization capacity - Google Patents

Pyrimidine Analogs -Ancitabine, Azacitidine, 6-Azauridine, Carmofur, Cytarabine, Doxifluridine, Enocitabine, Floxuridine, ...
more infohttps://patents.google.com/patent/WO2003000236A1/en

US Patent # 9,901,647. Conjugates comprising cell-binding agents and cytotoxic agents - Patents.comUS Patent # 9,901,647. Conjugates comprising cell-binding agents and cytotoxic agents - Patents.com

... pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, ...
more infohttp://patents.com/us-9901647.html

Application # 2018/0134794. ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET,
     AND METHODS OF USE...Application # 2018/0134794. ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE...

... analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, ...
more infohttps://patents.com/us-20180134794.html

NOVEL CHEMICAL COMPUNDS AND THEIR USE - BIOTA SCIENTIFIC MANAGEMENT PTY LTDNOVEL CHEMICAL COMPUNDS AND THEIR USE - BIOTA SCIENTIFIC MANAGEMENT PTY LTD

Antitumor agents such as, 5-fluorouracil and derivatives thereof, krestin, picibanil, ancitabine, cytarabine and the like; 26. ...
more infohttp://www.sumobrain.com/patents/wipo/Novel-chemical-compunds-their-use/WO2004050677.html

Patent US5202352 - Intravascular embolizing agent containing angiogenesis-inhibiting substance - Google PatentsPatent US5202352 - Intravascular embolizing agent containing angiogenesis-inhibiting substance - Google Patents

... ancitabine hydrochloride, enocitabine, azaserine and diazomycin; antibiotics such as actinomycin D, cyclomycin, mitomycin C, ...
more infohttp://www.google.com/patents/US5202352?dq=7800613

Natural Product Library | 天然产物化合物库 | MCE中国Natural Product Library | 天然产物化合物库 | MCE中国

Ancitabine (hydrochloride) Ipriflavone (S)-10-Hydroxycamptothecin Rotundine Guanosine Vanillin Empty. g. Empty. Astragaloside A ...
more infohttp://www.medchemexpress.cn/screening/Natural_Product_Library_.html

Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists - Genentech, Inc.Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists - Genentech, Inc.

... pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, ...
more infohttp://www.freepatentsonline.com/9895441.html

US Patent Application for ANTI-CD40 ANTIBODIES AND METHODS OF USE Patent Application (Application #20170246297 issued August 31...US Patent Application for ANTI-CD40 ANTIBODIES AND METHODS OF USE Patent Application (Application #20170246297 issued August 31...

... pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, ...
more infohttps://patents.justia.com/patent/20170246297

US Patent for Anti-CD40 antibodies Patent (Patent #  9,994,640 issued June 12, 2018) - Justia Patents SearchUS Patent for Anti-CD40 antibodies Patent (Patent # 9,994,640 issued June 12, 2018) - Justia Patents Search

... pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, ...
more infohttps://patents.justia.com/patent/9994640

Application # 2005/0002865. Diagnostic/therapeutic agents - Patents.comApplication # 2005/0002865. Diagnostic/therapeutic agents - Patents.com

... ancitabine, androstanediol, androstanol propionate, androstenetrione, androstenonol propionate, anethole, anguidine, anidoxime ...
more infohttp://www.patents.com/us-20050002865.html

ANTI-LRP6 ANTIBODIES - Patent applicationANTI-LRP6 ANTIBODIES - Patent application

... pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, ...
more infohttp://www.patentsencyclopedia.com/app/20140363439

ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS - Patent applicationARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS - Patent application

... analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, ...
more infohttp://www.patentsencyclopedia.com/app/20130281525

Indian Patents. 258133:C-MET ANTIBODIESIndian Patents. 258133:C-MET ANTIBODIES

... pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, ...
more infohttp://www.allindianpatents.com/patents/258133-c-met-antibodies

CA3027121A1 - Anti-gitr antibodies and uses thereof 
        - Google PatentsCA3027121A1 - Anti-gitr antibodies and uses thereof - Google Patents

... pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, ...
more infohttps://patents.google.com/patent/CA3027121A1/en

NAVER Academic > Search...NAVER Academic > Search...

Acute Disease, Adult, Ancitabine, adverse effects, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Daunorubicin, ...
more infohttps://academic.naver.com/search.naver?field=3&query=Acta+Haematologica+88%EA%B6%8C+1%ED%98%B8

List of drugs: An-Ap - WikipediaList of drugs: An-Ap - Wikipedia

... ancitabine (INN) Ancobon Ancotyl ancriviroc (USAN) ancrod (INN) andolast (INN) Andriol Androcur Androderm Androgel Android-f ...
more infohttps://en.wikipedia.org/wiki/List_of_drugs:_An-Ap

List of MeSH codes (D13) - WikipediaList of MeSH codes (D13) - Wikipedia

... ancitabine MeSH D13.570.685.245.500 --- deoxycytidine MeSH D13.570.685.245.500.250 --- bromodeoxycytidine MeSH D13.570.685.245. ... ancitabine MeSH D13.570.065.950 --- vidarabine MeSH D13.570.230.229 --- deoxyadenosines MeSH D13.570.230.229.075 --- cladribine ...
more infohttps://en.wikipedia.org/wiki/List_of_MeSH_codes_(D13)

Indian Patents. 207623:PHARMACEUTICAL COMPOUNDSIndian Patents. 207623:PHARMACEUTICAL COMPOUNDS

for antitumoral drugs, the following can be mentioned: ancitabine, anthramycin, azacitidine, azaserine, 6-azauridine, ...
more infohttp://www.allindianpatents.com/patents/207623-pharmaceutical-compounds

MEDICAL - THE ND PHARMA & BIOTECH COMPANYMEDICAL - THE ND PHARMA & BIOTECH COMPANY

Ancitabine. (s)-3-amino-(6-phenyl)-5-hexenoic Acid-hcl. (s)-3-amino-2-n-cbz-propanoic Acid. (s)-3-amino-4-(1-naphthyl)-butyric ...
more infohttp://www.ndpharmabiotech.net/medical.html

CAS No 10102-23-5 To 10294-33-4CAS No 10102-23-5 To 10294-33-4

Ancitabine hydrochloride C9H11N3O4.HCl 261.66. ...
more infohttps://www.guidechem.com/dictionary-95.html

Medical Isotopes, Inc.Medical Isotopes, Inc.

Ancitabine Synonyms:. Ancitabine hydrochloride; Cyclotidine; Cyclo-C; 2,2-Anhydro-(1-β-D-arabinofuranosyl) ...
more infohttp://www.medicalisotopes.com/product-category.php?id=216

GENERIC 75105GENERIC 75105

pubmed-meshheading:75105-Ancitabine, pubmed-meshheading:75105-Breast Neoplasms, pubmed-meshheading:75105-Cytarabine, pubmed- ... http://linkedlifedata.com/resource/pubmed/chemical/Ancitabine, http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine ...
more infohttp://linkedlifedata.com/resource/pubmed-article/75105?generic=true

No FAQ available that match "ancitabine"